Blocking Patents in Litigation After Acorda: What’s Acorda’s Impact Inside and Outside of Pharma?

Recorded On: 02/20/2020

  • Registration Closed

In its 2018 Acorda v. Roxane decision, the Federal Circuit addressed in detail the blocking patent doctrine, under which the potential deterrent effect of an earlier patent on subsequent innovation can discount or negate objective indicia of nonobviousness pertaining to a later invention. The decision was viewed as a threatening broadening of the doctrine by many in the pharmaceutical industry, where the doctrine developed in litigation. 

Last fall, the Supreme Court denied the petition for certiorari in the case. These two webinars will examine the impact of Acorda both within the pharma industry and without. The language of the decision leads some experts to believe the blocking patent doctrine enunciated in Acorda is applicable to any technology, and that the lengthy “Acorda factors” will soon join elder siblings like the Graham and Georgia-Pacific factors in patent lexicography. 

Depending on how courts react, Acorda raises many issues for patent prosecutors, notably how to protect inventions that represent an incremental improvement over existing patents.

On Thurs Feb. 20 the first part of this series, Blocking Patents in Litigation, will feature a panel with an in-house counsel at a global tech company and two veteran patent litigators. They will analyze whether Acorda is  a game changer in Hatch-Waxman litigation; whether the lesser role of secondary considerations will relegate Acorda to the sidelines in high tech patent litigation; and how the fact-specific inquiry required by Acorda will likely play out with discovery, expert testimony, and questions about the burden of proof.

Speakers: 

Elaine Blais, Goodwin Procter

David Manspeizer, Squire Patton Boggs

Frank Nuzzi, Siemens

Elaine Blais

Goodwin Procter

is a patent litigator and head of the Litigation Department in the Boston office of Goodwin Procter. An expert in biosimilar litigation, Elaine has handled numerous patent infringement lawsuits in federal courts nationwide involving diverse areas of technology including pharmaceutical products, biosimilars, secure financial transactions, semiconductor manufacturing tools, and consumer products 

David Manspeizer

Squire Patton Boggs

a partner at Squire Patton Boggs, has more than 25 years of experience counseling and representing industry-leading global pharmaceutical and biotechnology companies in complex patent litigation. He was head of IP at Wyeth from 2002 until its acquisition by Pfizer in 2009.

Frank Nuzzi

Siemens Corp.

is Senior Intellectual Property Counsel, IP Litigation, for Siemens Corporation, located in Iselin, New Jersey. He manages simple and complex U.S. patent litigation for Siemens. Prior to joining Siemens, Frank was in the litigation department of Clifford Chance.

Key:

Complete
Failed
Available
Locked
Blocking Patents in Litigation: What’s Acorda’s Impact Inside and Outside of Pharma?
02/20/2020 at 2:00 PM (EST)   |  60 minutes
02/20/2020 at 2:00 PM (EST)   |  60 minutes
Evaluation Survey
11 Questions
CLE Credit
4 Questions
4 Questions CLE credit will be available for registered attendees only. If you would like CLE credit for this webinar, please complete the following questions. IPO will apply for CLE for all live programs in the majority of the states that require CLE. IPO will not be applying for CLE in the states of Florida, Ohio, South Carolina, West Virginia, or Texas (attorneys in TX may submit up to 5 hours of self-study credit). Once IPO has received approval from the state(s) CLE boards , certificate(s) of attendance will be available for download from your dashboard.
ID Certificate of Attendance
Up to 1.00 CLE credits available  |  Certificate available
Up to 1.00 CLE credits available  |  Certificate available Idaho has approved this course for 1 hour of CLE credit. Only registered attendees that attended this course are eligible to claim credit. To claim your credit, select "Claim Credit" then "View/Print certificate" for your records.
IL Certificate of Attendance
Up to 1.00 CLE credits available  |  Certificate available
Up to 1.00 CLE credits available  |  Certificate available Illinois has approved this recording for 1 hour of CLE credit. Only registered attendees that viewed the program are eligible to claim credit. To claim your credit, select “claim credits” and then “view/print your certificate” for your records.
IN Certificate of Attendance
Up to 1.00 CLE credits available  |  Certificate available
Up to 1.00 CLE credits available  |  Certificate available Indiana has approved this course for 1.0 hour of CLE credit. Only registered attendees who viewed the program are eligible to claim credit. To claim your credit, select "Claim Credit" then "View/Print Certificate for your records".
MN Certificate of Attendance
Up to 1.00 CLE credits available  |  Certificate available
Up to 1.00 CLE credits available  |  Certificate available Minnesota has approved this course for 1 hour of CLE credit. Only registered attendees that viewed the program are eligible to claim credit. To claim your credit, select "Claim Credit" then "View/Print Certificate" for your records.
MO Certificate of Attendance
Up to 1.20 CLE credits available  |  Certificate available
Up to 1.20 CLE credits available  |  Certificate available Missouri has approved this course for 1.2 hours of CLE credit. Only registered attendees that viewed the program are eligible to claim credit. To claim your credit, select "Claim Credit" then "View/Print your Certificate" for your records.
NJ Certificate of Attendance
Up to 1.00 CLE credits available  |  Certificate available
Up to 1.00 CLE credits available  |  Certificate available New Jersey has approved this webinar for 1 hour of CLE credit. Only registered attendees that viewed the program are eligible to claim credit. To claim your credit, select "claim credits" and then "view/print your certificate" for your records.
PA Certificate of Attendance
Up to 1.00 CLE credits available  |  Certificate available
Up to 1.00 CLE credits available  |  Certificate available Pennsylvania has approved this course for 1 hour of CLE credit. Only registered attendees that viewed the program are eligible to claim credit. To claim your credit, select "Claim credit" then "View/Print certificate" for your records.
TN Certificate of Attendance
Up to 1.00 CLE credits available  |  Certificate available
Up to 1.00 CLE credits available  |  Certificate available Tennessee has approved this course for 1.0 hour of CLE credit. Only registered attendees that viewed the program are eligible to claim credit. To claim your credit, select "Claim Credit" then "View/Print your Certificate" for your records.
WA Certificate of Attendance
Up to 1.00 CLE credits available  |  Certificate available
Up to 1.00 CLE credits available  |  Certificate available Washington has approved this course for 1 hour of CLE credit. Only registered attendees that attended the program are eligible to claim credit. To claim your credit, select "Claim credit" then "View/Print certificate for your records.
Blocking Patents in Litigation After Acorda: What’s Acorda’s Impact Inside and Outside of Pharma? (RECORDING)
Open to view video.
Open to view video.